Psychedelics: A Better Way To Treat Depression
Marijuana Stocks, Finance, & InvestingUncategorized July 1, 2020 MJ Shareholders
Depression is depressing.
It is one of the most common medical disorders. Globally, depression is now estimated to afflict 322 million people [source: Anxiety and Depression Association of America]. Those numbers predate the surge in depression that has accompanied the COVID-19 pandemic.
Yet the success rate for treatment is dismal. And existing drugs on the market to treat depression are problematic, at best.
For all of these reasons, there is considerable excitement among a growing segment of medical professionals about the potential of psychedelic drugs for the treatment of depression.
A headline from The Guardian illustrates these sentiments.
More on this later. First, a closer look at the issue itself.
Huge problem
In the United States, 7.1% of all adults experienced a major depressive episode in the past year (based on 2017 data). That translates into 11 million Americans per year.
But it’s when we look at the treatment of depression that the numbers get really depressing. A study by Columbia University Medical Center and the University of Pennsylvania found that less than 1/3rd of Americans “who screened positive for depression received treatment for their symptoms”.
New findings suggest that most Americans with depression receive no treatment, while raising the possibility that overtreatment of depression is also widespread. Less than a third of American adults who screened positive for depression received treatment for their symptoms, whereas over two-thirds of adults receiving treatment for depression did not report symptoms of depression or serious psychological distress, according to a study from Columbia University Medical Center (CUMC) and the University of Pennsylvania.
Depressing.
Why do more than two out of three sufferers of depression not obtain treatment? It’s because existing drugs used to treat depression have a dismal success rate. The study outlines this failure.
Despite the introduction of newer-generation antidepressants, approximately 50% of patients experience non-response to treatment with a first-line antidepressant.
A 50% failure rate. Not good medicine.
It gets worse. Naturally, antidepressants are the primary “first-line” drug being prescribed for depression.
They don’t work.
Desperate need for a better treatment
Consistently in laboratory testing, antidepressants demonstrate a level of effectiveness that is (at best) only marginally better than placebos – sugar pills. A 2019 article in Medical News Today outlines the debate, and the latest research.
Put another way, antidepressants are, themselves, little more than placebos. They generate near-zero medicinal benefit beyond the placebo effect itself.
But they are potentially harmful – even dangerous. They cause serious side effects. A WebMD article compiles a list.
-
increased appetite and weight gain
-
loss of sexual desire and other sexual problems, such as erectile dysfunction and decreased orgasm
-
fatigue and drowsiness
-
blurred vision
-
constipation
-
irritability
This article from the National Institute of Health (NIH) paints an even darker picture.
In 2004, the FDA required a boxed (“black box”) warning to be added to package inserts for antidepressants in order to call attention to an increased risk of suicidal thoughts and behavior (suicidality) in children and adolescents taking these drugs. In 2007, the FDA extended the age range covered by the warning to include young adults up to 24 years of age. [emphasis mine]
Sugar pills have similar efficacy to antidepressants. But they don’t cause nausea, fatigue and drowsiness, blurred vision, constipation, dizziness, agitation, irritability, or anxiety. And they certainly don’t cause people to commit suicide.
Antidepressants have a dismal failure rate. They pose numerous serious (and even dangerous) side effects. They are being prescribed even though only a minority of users will derive any actual medicinal benefit.
Despite these shortcomings, Big Pharma has programmed doctors to prescribe antidepressants like two-legged Pez dispensers.
A 2017 article from Time Magazine (the most recent data available) indicated that 13% of Americans 12 years of age or older were currently being prescribed antidepressants.
This leads to another major downside for anti-depressants: they are very addictive. This 2018 New York Times article illustrates the bleak reality.
Long-term use of antidepressants is surging in the United States, according to a new analysis of federal data by The New York Times. Some 15.5 million Americans have been taking the medications for at least five years. The rate has almost doubled since 2010, and more than tripled since 2000.
Nearly 25 million adults, like Ms. Toline, have been on antidepressants for at least two years, a 60 percent increase since 2010.
The drugs have helped millions of people ease depression and anxiety, and are widely regarded as milestones in psychiatric treatment. Many, perhaps most, people stop the medications without significant trouble. But the rise in longtime use is also the result of an unanticipated and growing problem: Many who try to quit say they cannot because of withdrawal symptoms they were never warned about.
Claiming these drugs have “helped millions of people” is highly dubious for reasons already explained. Most of those people would have derived just as much benefit taking sugar pills for all those years – minus the drug addiction.
While the medicinal benefit of anti-depressants is debatable, the addiction and dangerous side effects are all too real.
Solution on the horizon
The medical profession desperately needs a viable alternative to anti-depressants for the treatment of depression.
Enter psychedelics.
Even if there were currently adequate treatment options for depression, emerging results from clinical studies involving psychedelics would be regarded as potentially revolutionary.
- A 2016 study on the use of psychedelic drugs by terminally-ill patients showed that 80% experienced reduced depression and anxiety
- A 2016 study on “treatment-resistant depression” reported that two-thirds of patients (66%) were in remission one week after their first psilocybin therapy session
Far superior to the placebo-like efficacy of anti-depressants.
Based upon these results and other studies on psychedelic drugs for depression, the FDA has granted private psychedelics company Compass Pathways “breakthrough therapy” designation for its own clinical research in this area.
To quote the October 2018 press release from Compass Pathways:
The two take-aways here:
– Psilocybin therapy for the treatment of depression is regarded as a (potentially) substantial improvement over existing treatment options
– Psychedelics-based research in this area is being fast-tracked for regulatory approval
The timing of this breakthrough could not be better.
Thanks to the global pandemic and the lockdowns associated with it, there has been a huge spike in the number of people experiencing symptoms of depression along with the severity of those symptoms.
According to Statista, the number of U.S. adults currently experiencing “symptoms of depressive disorder” has nearly quadrupled in 2020 to 24.4% versus 6.6% from the same time last year.
The global epidemic of depression isn’t going to go away, even if the rise in sufferers levels off.
Anti-depressants aren’t suddenly going to start working better. They are not going to stop causing dangerous side effects. They are not going to cease to be addictive.
This is a multi-billion dollar treatment market and growing.
For investors, putting all of this together spells opportunity. Compass Pathways is still a private company although rumors have been swirling for well over a year about plans to go public.
Bloomberg stoked those rumors again in February of this year.
Other companies and institutions engaging in psychedelics-based research are also targeting depression.
Other psychedelic drugs being used in such research include ayahuasca (Phase II clinical study), ketamine (numerous clinical studies), LSD (Phase II clinical study), as well as other psilocybin-based research [source: Report on Psychedelics – Volume II, Neo Exchange].
Depression is depressing. But there is new hope.
Psychedelics-based research shows great promise in revolutionizing the treatment of this global health epidemic.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
